Zivo Bioscience, Inc.

53 articles about Zivo Bioscience, Inc.

• Zivo Bioscience, Inc. Announces Closing of Underwriters’ Partial Exercise of Over-Allotment Option in Connection with its Previously Announced Public Offering

  7/2/2021

  Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary algal cultures, today announced the closing of the sale of an additional 150,000 shares of common stock,

• Zivo Bioscience, Inc. Announces Closing of Upsized $13.8 Million Public Offering and Uplisting to Nasdaq

  6/2/2021

  Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary algal cultures, today announced the closing of its previously announced underwritten public offering of 2,760,000 units at a price to the public of $5.00 per unit.

• ZIVO Bioscience to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

  6/2/2021

  ZIVO Bioscience, Inc. (NASDAQ:ZIVO), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional bioproduct candidates originally derived from proprietary algal cultures, today announced that President & Chief Executive Officer Andrew Dahl will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 – 10, 2021.

• Zivo Bioscience, Inc. Announces Pricing of Upsized $13.8 Million Public Offering and Up-listing to Nasdaq

  5/27/2021

  Zivo Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of nutritional/nutraceutical product candidates originally derived from proprietary algal cultures, today announced the pricing of its upsized underwritten public offering of 2,760,000 units at a price to the public of $5.00 per unit.

• ZIVO Bioscience Announces US Patent Office Notice of Allowance for Administration of Proprietary Algal Biomass to Support Immune Health

  4/26/2021

  ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of nutritional/nutraceutical product candidates originally derived from proprietary algal cultures, announces today the US Patent Office has issued a Notice of Allowance for the use of the company’s proprietary algal biomass product to promote a healthy immune response for use in dairy cattle.

• ZIVO Bioscience to Participate in Maxim Group’s Inaugural Emerging Growth Virtual Conference

  3/11/2021

  ZIVO Bioscience, Inc. ( OTCQB: ZIVO ),  a biotech/agtech R&D company engaged in the development and commercialization of therapeutic and additive product candidates originally derived from proprietary algal cultures, announces that CEO Andrew A. Dahl will present at Maxim Group’s Inaugural Emerging Growth Virtual Conference to be held March 17-18, 2021.

• ZIVO Bioscience Successfully Confirms Poultry Growth Promotion and Feed Conversion Ratio Improvements in Typical Production Environments

  1/11/2021

  ZIVO Bioscience, Inc. announces that in its recent analysis of two poultry studies performed at separate research facilities, ZIVO product candidates provided statistically significant feed conversion benefits in healthy broiler flocks exposed to pathogens present in litter from previous flocks, emulating exposure that may occur in a typical broiler production environment.

• Largest Shareholder of ZIVO Bioscience to Extend Maturity Date of Its Convertible Debt

  2/13/2018

  In a related filing, HEP has agreed to extend the maturity date on $16.7 million of its Secured Convertible Promissory Note, including all related interest payments, from September 30, 2018 to April 1, 2019.

• ZIVO Bioscience and Tianjin Norland Biotech Execute Letter of Intent to Produce ZIVO Algae Strain in China for International and Domestic Markets

  2/1/2018

  ZIVO anticipates that it will enter into a definitive, binding production agreement with Norland later in 2018.

• ZIVO Bioscience Annual Shareholder Meeting and Conference Call Slated for November 8, 2017 in Detroit, Michigan

  11/7/2017

  The Company's management will share its progress on various research and product development efforts over the past year.

• Zivo Bioscience, Inc. And Nutriquest Conclude Two Poultry Studies With Positive Results, Continue To Move Forward With FDA Compliance

  9/19/2017

• Zivo Bioscience, Inc. Kicks Off Final Phase Of Bovine Mastitis Study

  9/11/2017

• Zivo Bioscience, Inc. Enters Into Pilot Program To Expand Production Into Europe, Contracts With Algatek Asturias, S.L.

  7/11/2017

• Zivo Bioscience, Inc. : Midyear CEO Report – May 2017

  5/2/2017

• Zivo Bioscience, Inc. Executes Definitive Agreement With NutriQuest, Commences Poultry Field Trial

  4/27/2017

• Zivo Bioscience, Inc. Debuts New Corporate Website, Shareholder Outreach

  3/23/2017

• Zivo Bioscience, Inc. Executes Debt Restructuring With Private Equity Firm Hep Investments, LLC

  3/7/2017

• Zivo Bioscience, Inc. Expands Algae Cultivation For Compliance And Scaling Studies

  2/2/2017

• Zivo Bioscience, Inc. And NutriQuest Execute Agreement To Jointly Pursue New Feed And Feed Additive Solutions For Poultry And Swine Nutritional Applications

  12/15/2016

• Zivo Bioscience, Inc. Granted New US Patent For Healthy Cholesterol Balance

  11/30/2016